PJP:NYE-Invesco Dynamic Pharmaceuticals ETF (USD)

ETF | Health |

Last Closing

USD 86.65

Change

-0.35 (-0.40)%

Market Cap

N/A

Volume

6.23K

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-24 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

-0.31 (-0.20%)

USD 42.10B
FHLC Fidelity® MSCI Health Care In..

-0.12 (-0.16%)

USD 3.01B
FXH First Trust Health Care AlphaD..

-0.50 (-0.45%)

USD 1.29B
XHE SPDR® S&P Health Care Equipme..

-0.47 (-0.52%)

USD 0.23B
IDNA iShares Genomics Immunology an..

+0.10 (+0.41%)

USD 0.14B
SBIO ALPS Medical Breakthroughs ETF

-0.19 (-0.49%)

USD 0.12B
XHS SPDR® S&P Health Care Service..

-0.39 (-0.40%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

+0.06 (+0.19%)

USD 0.06B
BBP Virtus LifeSci Biotech Product..

-0.08 (-0.13%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

+0.16 (+0.55%)

USD 0.01B

ETFs Containing PJP

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 13.86% 81% B- 67% D+
Dividend Return 0.76% 69% C- 16% F
Total Return 14.63% 86% B+ 63% D
Trailing 12 Months  
Capital Gain 17.57% 38% F 52% F
Dividend Return 1.05% 61% D- 13% F
Total Return 18.62% 38% F 46% F
Trailing 5 Years  
Capital Gain 53.23% 62% D 71% C-
Dividend Return 4.22% 61% D- 12% F
Total Return 57.45% 57% F 68% D+
Average Annual (5 Year Horizon)  
Capital Gain 6.55% 57% F 60% D-
Dividend Return 7.14% 57% F 55% F
Total Return 0.59% 58% F 14% F
Risk Return Profile  
Volatility (Standard Deviation) 12.89% 67% D+ 70% C-
Risk Adjusted Return 55.40% 67% D+ 72% C
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike